Thromboembolic Events in JAK inhibitors: A Pharmacovigilance Study From 2012 to 2021 Based on FAERS.
Sign Up to like & getrecommendations! Published in 2022 at "British journal of clinical pharmacology"
DOI: 10.1111/bcp.15361
Abstract: INTRODUCTION As a new type of drug developed rapidly in recent years, Janus kinase inhibitors (JAKinibs) have caused controversy due to possible adverse reactions of thromboembolism. The aim of this study was to analyze and… read more here.
Keywords: thrombosis ror025; ror025; study; ror025 ic025 ... See more keywords
Hemophagocytic lymphohistiocytosis and disseminated intravascular coagulation are underestimated, but fatal adverse events in chimeric antigen receptor T-cell therapy.
Sign Up to like & getrecommendations! Published in 2023 at "Haematologica"
DOI: 10.3324/haematol.2022.281455
Abstract: Hematotoxicity is the most common long-term adverse event (AE) after chimeric antigen receptor T-cell (CAR-T) therapy. However, patients who receive CAR-T therapy in pivotal clinical trials are subjected to restrictive selection criteria, always causing an… read more here.
Keywords: cell; aes; therapy; car ... See more keywords